STAT

Opinion: Diversity in clinical trials defines good science and better medicine

Diversity in clinical trials remains low despite a 25-year-old law that requires all federally funded clinical research to prioritize including underserved racial and ethnic groups.

Hispanic Americans have higher levels of diabetes and less access to health care services, yet they live on average about three years longer than non-Hispanic whites and six years longer than African-Americans.

Why?

No one really knows. Hispanics are underrepresented in both clinical trials and the genome-wide association studies that have informed our understanding of the molecular foundation of health and disease, so we can only guess.

But new research is offering some insights. A study suggests that people age differently based

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min readChemistry
STAT+: Pharmalittle: We’re Reading About Fake Studies, AbbVie Investing In Psychedelics, And More
Fake studies have flooded publishers of top scientific journals,. leading to thousands of retractions and millions of dollars in lost revenue.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.
STAT1 min read
Opinion: STAT+: How AI Can Help Satisfy FDA’s Drug, Device Diversity Requirements
To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.

Related Books & Audiobooks